Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch

Transplantation

Volumn 97, Issue 12, 2014, Pages 1247-1252

  Riella, Leonardo V ^a   Safa, Kassem ^a   Yagan, Jude ^a   Lee, Belinda ^a   Azzi, Jamil ^a   Najafian, Nader ^a   Abdi, Reza ^a   Milford, Edgar ^a   Mah, Helen ^a   Gabardi, Steven ^a   Malek, Sayeed ^a   Tullius, Stefan G ^a   Magee, Colm ^b   Chandraker, Anil ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BEAUMONT HOSPITAL   (Ireland)

Author keywords

Alloantibodies; CDC crossmatch; Desensitization; Kidney transplantation

Indexed keywords

BASILIXIMAB; CREATININE; IMMUNOGLOBULIN; RITUXIMAB;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DESENSITIZATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALE; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; RECIPIENT;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BOSTON; COMBINED MODALITY THERAPY; COMMUNICABLE DISEASES; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; NEOPLASMS; PLASMAPHERESIS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902485150     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000442782.98131.7c     Document Type: Article

References (31)

1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR) OPTN/SRTR 2010 Annual Data Report.
2. Katerinis I, Hadaya K, Duquesnoy R, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 2011; 11: 1727.
3. Selin LK, Brehm MA. Frontiers in nephrology: heterologous immunity, T cell cross-reactivity, and alloreactivity. J Am Soc Nephrol 2007; 18: 2268. PubMed.
4. Gloor J, Stegall MD. Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol 2010; 6: 297.
5. Marfo K, Lu A, Ling M, et al. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011; 6: 922.
6. Segev DL, Gentry SE, Warren DS, et al. Kidney paired donation and optimizing the use of live donor organs. JAMA 2005; 293: 1883.
7. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
8. Alachkar N, Lonze BE, Zachary AA, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012; 94: 165.
9. Nair V, Sawinski D, Akalin E, et al. Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. Clin Transplant 2012; 26: E261.
10. Stegall MD, Gloor J,Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
11. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9: 536.
12. Magee CC, Felgueiras J, Tinckam K, et al. Renal transplantation in patients with positive lymphocytotoxicity crossmatches: one center's experience. Transplantation 2008; 86: 96.
13. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004; 8: 535.
14. Thielke JJ, West-Thielke PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. Transplantation 2009; 87: 268.
15. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
16. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLAincompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
17. Gentry SE, Segev DL, Montgomery RA. A comparison of populations served by kidney paired donation and list paired donation. Am J Transplant 2005; 5: 1914.
18. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582.
19. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9: 1099.
20. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242.
21. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13: 76.
22. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405.
23. Diwan TS, Raghavaiah S, Burns JM, et al. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation 2011; 91: 536.
24. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
25. Everly MJ, Everly JJ, Susskind B, et al. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc 2009; 41: 105.
26. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215.
27. Ulrich C, Kanitakis J, Stockfleth E, et al. Skin cancer in organ transplant recipientsVwhere do we stand today? Am J Transplant 2008; 8: 2192.
28. Magee CC, Mah H, Tinckam K, et al. Successful living donor kidney transplantation across HLA and ABO incompatibilities. Nephrol Dial Transplant 2007; 22: 602.
29. Tinckam KJ, Wood IG, Ji F, et al. ATG induction is associated with an increase in anti-HLA antibodies after kidney transplantation. Hum Immunol 2004; 65: 1281.
30. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
31. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteriaVan addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.